Pharmaxis Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Pharmaxis Ltd with three other companies in this sector in Australia: Bionomics Limited (2017 sales of 18.61 million Australian Dollars [US$14.15 million] of which 88% was Drug discovery and development), Tempo Australia Limited (18.51 million Australian Dollars [US$14.07 million] ), and Clinuvel Pharmaceuticals Limited (17.03 million Australian Dollars [US$12.95 million] of which 100% was Biotechnology).

Sales Analysis. During the year ended June of 2017, sales at Pharmaxis Ltd were A$17.64 million (US$13.41 million). This is a decrease of 5.0% versus 2016, when the company's sales were A$18.57 million. Contributing to the drop in overall sales was the 9.2% decline in Bronchitol and Aridol, from A$14.91 million to A$13.54 million. . However, these declines were partially offset by the increase in sales of New Drug Development (up 32.4% to A$3.42 million) and Corporate (up 6.3% to A$337,000.00 ) .